StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Stock analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.

Aptevo Therapeutics Trading Down 15.2 %

Shares of Aptevo Therapeutics stock opened at $0.24 on Friday. Aptevo Therapeutics has a 52-week low of $0.14 and a 52-week high of $10.80. The company’s 50-day simple moving average is $0.23 and its 200-day simple moving average is $0.39.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.